CLOs on the Move

UHSM Health Sharing

www.uhsm.com

 
UHSM is not health insurance; we do healthcare sharing differently. Multiple Christian healthcare options offer a fresh approach to healthcare that exceeds expectations.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.uhsm.com
  • 999, Waterside Drive
    Norfolk, VA USA 23510
  • Phone: +20.800.900.8476

Executives

Name Title Contact Details

Similar Companies

Health Care and Rehabilitation Services

Founded in 1967, HCRS is a non-profit, community mental health agency serving Vermonters in Windham and Windsor counties. HCRS serves over 4,000 individuals every year through its mental health, substance abuse, and developmental disabilities programs. The Agency provides a wide range of social services that support optimal mental health and functioning.

Access Physicians

Access Physicians is a physician-founded, multispecialty group that is improving outcomes by increasing access to exceptional care through telemedicine.

Hobbs Medical Inc

Hobbs Medical Inc is a Stafford Springs, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Planned Parenthood Alhambra Health Center

Planned Parenthood Alhambra Health Center is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.